Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead

The Core Frame: China and India Are Playing Different Pharma Games

India and China are both pharmaceutical powers, but they sit in different parts of the value chain.

India’s strength is downstream: formulations, generics, vaccines, regulatory filing capacity, export scale and cost-efficient finished-dose manufacturing.

China’s strength is upstream and increasingly innovation-led: APIs, KSMs, fermentation chemistry, complex intermediates, large-scale chemical manufacturing and now early-stage biotech licensing.

That difference decides who gets hit harder when supply-chain stress rises.

This is the core asymmetry. India is a global medicine supplier. China is a supplier to the suppliers.

India’s Exposed Point: The API/KSM Problem

India’s pharma export story is strong. The country is one of the world’s largest suppliers of generic medicines and vaccines, and its pharma exports crossed $30 billion in FY 2024–25. The long-term industry ambition remains large, with India’s pharma sector widely projected toward $130 billion by 2030.

But export scale does not automatically mean input security.

For several APIs, India still depends heavily on China. The Indian government has identified APIs for which imports from China accounted for 70% or more of India’s total imports in FY2023–24 and FY2024–25. That means India’s exposure is not theoretical. It exists at the level of specific molecules and bulk-drug inputs.

This matters because generic manufacturing is a low-margin business. When input costs rise, companies cannot always pass costs forward quickly. Export contracts, price controls, tender pricing and competitive generic markets limit pricing flexibility.

So when an oil and freight shock hits, Indian pharma faces pressure from two sides: input dependence, and thin-margin finished-drug economics.

That is the part the market often misses. India may be strong in finished products, but many finished products still rest on an upstream chemistry chain where China is dominant.

China’s Position: Not Immune, But Better Placed in Pharma Chokepoints

China is not immune to the Iran war. A large share of China’s crude oil imports passes through the Strait of Hormuz, and disruption creates real energy-security pressure. China may have stockpiles, alternative supply channels and stronger state-directed buffers, but it still cannot ignore the oil shock.

The difference is that, inside pharma, China controls more of the input layer.

For India, a Chinese API or KSM disruption is a production problem. For China, the same upstream chemistry is an industrial advantage.

That advantage is now extending beyond manufacturing. China is also becoming an innovation supplier to global pharma. Greater China licensing deal values reached record levels in 2025, with multinational drugmakers increasingly licensing Chinese-origin assets. AstraZeneca’s up to $18.5 billion deal with China’s CSPC for weight-loss and related drug programs is one major example.

This changes the old map. China is no longer only the low-cost chemical factory. It is becoming a source of early-stage drug candidates.

That means China controls two layers of leverage: the old API/KSM chokepoint, and the newer biotech licensing chokepoint.

The Iran War Transmission: Oil, Freight and Working Capital

The Iran war transmits into pharma through cost and uncertainty. It does not need to stop every shipment to hurt manufacturers. It only needs to raise the price of movement, energy and risk.

The chain looks like this:

This is why India is more exposed on the pharma channel. A high-margin branded innovator can absorb some cost shock. A low-margin generic exporter cannot always do that. A company with integrated upstream chemistry can manage disruption better. A company importing key starting materials from another country has less room to move.

The war therefore acts like a stress test. It does not hit all pharma models equally. It hits the model that depends on cheap inputs, cheap energy and reliable logistics the hardest.

The China Plus One Trap

The phrase “China plus one” sounds simple. Move some manufacturing out of China and build redundancy in India or Southeast Asia.

In pharma, that is harder than it sounds.

A final formulation plant in India does not automatically remove China dependence if the API or KSM still comes from China. A final API plant does not fully solve the problem if the hazardous, energy-intensive, chemistry-heavy KSM stage still sits in China.

That is the trap. India can build more downstream capacity, but the root problem remains upstream. Fermentation-based APIs, complex intermediates, hazardous chemistry and energy-intensive processes require time, scale, environmental approvals, cost competitiveness and deep process know-how.

India’s PLI bulk-drug push is important. It shows the government understands the problem. But building upstream resilience is not the same as announcing policy. It requires commercial viability.

When oil rises, domestic production can become more expensive too. That weakens the economics of the very capacity India needs to build.

So the Iran war does not only expose India’s dependence. It can also make de-risking more expensive.

Why China’s Innovation Lead Changes the Story

If China were only an API supplier, the story would be simpler. But China’s biotech licensing boom changes the strategic map.

Global pharma companies are licensing Chinese drug candidates because they need faster, cheaper and more diverse pipeline options. Patent cliffs, R&D cost pressure and oncology/metabolic competition are pushing Western pharma toward external innovation. Chinese biotech companies are now supplying more of that innovation.

This matters because innovation sits above manufacturing tariffs and freight shocks. Oil can raise the cost of moving goods. It does not easily destroy the value of intellectual property, clinical programs or licensing optionality.

That is why China’s newer advantage is more durable than its old one.

API and KSM dominance gives China supply-chain leverage. Biotech licensing gives China strategic innovation leverage.

India’s current pharma power is still mostly in finished medicines. That is valuable, but it is not the same as controlling the molecule, the input chemistry or the early-stage intellectual property.

India’s Strength Should Not Be Undervalued

This is not an anti-India argument.

India remains one of the world’s most important pharmaceutical suppliers. Its export reach, formulation capacity, regulatory experience, generic manufacturing base and vaccine strength are difficult to replicate. The world cannot easily replace India’s finished-drug contribution.

But the lesson is not that India is weak. The lesson is that India’s strength is incomplete.

A country can dominate finished generics and still be vulnerable if upstream chemistry remains externally controlled. A company can export globally and still be exposed if key inputs are concentrated in one foreign supply base. A pharma sector can grow rapidly and still carry structural risk if energy, APIs, KSMs and logistics become more expensive together.

That is India’s challenge.

China’s Risk Is Political, Not Only Logistical

China’s pharma advantage is not risk-free.

Its biggest vulnerability is increasingly political. US and Western scrutiny of China-linked biotech deals, API sourcing, national security, technology transfer and pharma supply dependence is rising. China’s innovation exports may face greater review if policymakers begin treating biotech like semiconductors or critical minerals.

That is the real counterweight. The Iran war does not directly hit China’s biotech licensing engine. But geopolitics can.

So China’s exposure is not absent. It is different.

India is more exposed to cost and input dependency. China is more exposed to strategic containment and political risk. That distinction matters.

The Investor Read

For investors, this is not just a macro story. It is a margin story and a supply-chain-quality story.

Indian generic companies with high dependence on imported APIs, low pricing power and export-heavy exposure could face pressure if input and logistics costs rise together. Companies with backward integration, diversified sourcing, better inventory discipline and higher-value products may look stronger.

Chinese API and biotech companies may retain strategic leverage, but investors must account for political-risk discounts, especially where licensing deals, US partnerships or sensitive technologies are involved.

The investment question is not simply: which country sells more medicines? The sharper question is: Who controls the part of the chain that becomes scarce when the system is stressed?

The CEO Lesson

The Iran war gives pharma CEOs one hard lesson: supply-chain resilience is no longer a procurement function. It is strategy.

A CEO should know:

• which APIs depend on China,
• which KSMs have no alternative source,
• which products have thin margin and high input volatility,
• which export contracts cannot absorb cost changes,
• which suppliers are oil-sensitive,
• which products need safety stock,
• which customers need early warning if supply conditions change,
• and which molecules are strategically too important to leave exposed.

The old model optimized for cost. The new model must optimize for resilience.